Table 5 Base-Case Results for nusinersen versus BSC in the health care sector perspective
From: Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
| Drug treatment costs* | Non-treatment health care costs* | Total costs* | QALYs | LYs | Incremental results | ||
|---|---|---|---|---|---|---|---|
| Cost/QALY gained* | Cost/LY gained* | ||||||
| Nusinersen | $2,231,000 | $1,653,000 | $3,884,000 | 3.24 | 7.64 | $1,112,000 | $590,000 |
| BSC | $0 | $789,000 | $789,000 | 0.46 | 2.40 | – | – |